ERBB2 and breast carcinoma: The introduction of the monoclonal antibody trastuzumab as the first HER2-specific targeted therapy led to tremendous improvement in recurrence-free survival and overall survival (OS) in early breast cancer [2] and progression-free survival (PFS) and OS in metastatic disease [3].